UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000000959 |
|---|---|
| Receipt number | R000001149 |
| Scientific Title | Combination therapy of the peptide vaccines and dexamethasone for hormone-refractory prostate cancer: Early phase II randomized controlled study |
| Date of disclosure of the study information | 2008/01/01 |
| Last modified on | 2015/05/13 16:26:44 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Combination therapy of the peptide vaccines and dexamethasone for hormone-refractory prostate cancer: Early phase II randomized controlled study
Acronym
Combination therapy of the peptide vaccines and dexamethasone for hormone-refractory prostate cancer
Scientific Title
Combination therapy of the peptide vaccines and dexamethasone for hormone-refractory prostate cancer: Early phase II randomized controlled study
Scientific Title:Acronym
Combination therapy of the peptide vaccines and dexamethasone for hormone-refractory prostate cancer
Region
| Japan |
Condition
Condition
Progressive hormone-refractory prostate cancer
Classification by specialty
| Urology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Candidate peptide vaccines have been developed for the prostate cancer patients who have HLA-A2, HLA-A24, or HLA-A3 super type.
Of these peptides, we plan to use as vaccines those that have been recognized by the patient-specific immune system (serum IgG antibodies) or by the killer T-cell precursor (CTLp) in the peripheral blood.
If the patient is positive for two of the HLA super types, both candidate peptides will be selected as vaccines.
We will evaluate the safety and efficacy of combination therapy of peptide vaccines and dexamethasone compared with dexamethasone alone against prostate cancer patients by a prospective randomized controlled trial.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase I,II
Assessment
Primary outcomes
Progression-free survival
Objective response rate
Disease control rate
Safety profile
Evaluation will be performed on each evaluable lesion according to The Prostate Cancer Treatment Agreement in Japan (3rd edition. April, 2001).
When the patient does not have measurable lesions, the serum PSA level will be assessed in accordance with Bubley's criteria.
The initial evaluation will be performed 12 weeks after the initiation of treatment.
Key secondary outcomes
Immune response:
Induction of cytotoxic T-lymphocytes and CTL-precursor cells.
Induction of the anti-peptide antibodies.
Immune response will be assessed by comparing the data from samples obtained before and after therapy administration.
QOL score
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -but assessor(s) are blinded
Control
Active
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine | Vaccine |
Interventions/Control_1
Combination of the peptides and dexamethasone:
Maximum of four kinds of peptide from those that have been recognized by the patient-specific immune system (serum IgG antibodies) or by the killer T-cell precursor (CTLp) in the peripheral blood will be selected as vaccines.
3mg of each peptide will be administrated separately.
The administration interval is essentially 2 weeks.
Dose reduction to 1 mg is allowed when a grade-3 adverse event of local skin response occur.
Dexamethasone 1 mg/day p.o. everyday is started on the first day of peptide administration.
Essentially, peptides and dexamethasone administration will be continued until disease progression or severe adverse events occur.
Interventions/Control_2
Dexamethasone alone:
Dexamethasone 1 mg/day p.o. everyday is started on the first day of peptide administration.
Essentially, dexamethasone administration will be continued until disease progression or severe adverse events occur.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male
Key inclusion criteria
Eligible patients must meet the following criteria:
1. Hormone-refractory prostate cancer patients who have been histologically diagnosed as prostate adenocarcinoma.
Hormone-refractory prostate cancer is defined as the disease that has progressed after remission by primary hormone therapy with antiandrogens and surgical or medical castration.
Patients should have at least one measurable lesion 2 cm or larger by X-ray or should have consecutively-rising PSA detected three or more times by at least two-week interval evaluation after reaching the nadir by primary hormone therapy.
Antiandrogen-withdrawal syndrome should be ruled out by ceasing the antiandrogen for at least six weeks.
LH-RH agonist (leuprolide acetate, Leuplin) administration should be continued to maintain serum testosterone within castration levels when surgical castration has not been performed.
2. Patients are positive for HLA-A2, HLA-A24, or HLA-A3 super types (A3, A11, A31, A33).
3. Patients who have IgG or killer T-cell precursor that respond to one or more peptides prepared as candidate vaccines in the peripheral blood before vaccine administration.
4. No adverse effects or events occurring as a resulted from prior treatment should be carried over. Four or more weeks are required to wash out the pretreatment drug.
5. The patients' performance status (ECOG) should be 0 or 1.
6. Expected survival time should be three months or greater.
7. Serum PSA less than 10.0ng/ml
8. Written consent of participation after thorough explanation regarding this trial is required.
Key exclusion criteria
Any patient who falls under any of the following criteria is excluded as a candidate:
1. Patients who have any severe underlying medical condition such as severe active infection, cardiovascular disease, respiratory disease, renal dysfunction, immune dysfunction, blood coagulation disorder and so on.
2. Active double cancer.
3. Past history of severe allergic disease.
4. Patients previously treated with an adrenocortical steroid such as dexamethasone. Temporary use of a steroid against a non-prostate cancer related diseases, for example allergies, are not excluded.
5. Patients previously treated with systemic chemotherapy including Docetaxel and Cisplatin or radiotherapy against non-primary disease.
6. Hepatitis type B or C should be excluded.
7. Any patients disqualified by a study physician.
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hirotsugu Uemura |
Organization
Kinki University School of Medicine
Division name
Department of Urology
Zip code
Address
377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan
TEL
072-366-0221
huemura@med.kindai.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hirotsugu Uemura |
Organization
Kinki University School of Medicine
Division name
Department of Urology
Zip code
Address
377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan
TEL
072-366-0221
Homepage URL
huemura@med.kindai.ac.jp
Sponsor or person
Institute
Department of Urology, Kinki University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Jikei University School of Medicine
Osaka University, Graduate school of Medicine
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2008 | Year | 01 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2007 | Year | 12 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2008 | Year | 01 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 05 | Month | 13 | Day |
Date of closure to data entry
| 2015 | Year | 05 | Month | 13 | Day |
Date trial data considered complete
| 2015 | Year | 05 | Month | 13 | Day |
Date analysis concluded
| 2015 | Year | 05 | Month | 13 | Day |
Other
Other related information
Management information
Registered date
| 2007 | Year | 12 | Month | 28 | Day |
Last modified on
| 2015 | Year | 05 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001149
